By M&A — Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases PR Newswire
Auto-published by the finit.news Events monitor from M&A; summarized by AI and may contain errors — verify against the primary source. August 31, 2026.